vactosertib (TEW-7197) / National OncoVenture, Theragen Etex 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   14 News 


1234»
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Vactosertib, a TGF-? signaling inhibitor, in combination with durvalumab increased mOS in ?2L treatment of patients with PD-L1-positive advanced NSCLC (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1424;    
    P1b/2a
    Vincent's Hospital (VC19MDDF0205), and Chungbuk National University Hospital (2019-08-015).View this table:View inline View popup Download powerpoint Abstract 605 Table 1 Antitumor activity by treatment group for patients with advanced NSCLC. [Abbreviation] TGF-?; Targeting transforming growth factor-?, TME; tumor microenvironment, ICI; immune checkpoint inhibitors, NSCLC; non-small lung cancer, ORR; objective response rate, mDOR; median duration of response, mTTR; median time to objective response, mPFS; median progression-free survival, mOS; median overall survival, TEAEs; treatment-emergent adverse events
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases (clinicaltrials.gov) -  Sep 19, 2024   
    P2,  N=19, Recruiting, 
    [Abbreviation] TGF-?; Targeting transforming growth factor-?, TME; tumor microenvironment, ICI; immune checkpoint inhibitors, NSCLC; non-small lung cancer, ORR; objective response rate, mDOR; median duration of response, mTTR; median time to objective response, mPFS; median progression-free survival, mOS; median overall survival, TEAEs; treatment-emergent adverse events Trial completion date: Jun 2024 --> Jan 2027 | Trial primary completion date: Jun 2024 --> Jan 2027
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Preclinical, Journal:  Mechanisms of retinal photoreceptor loss in spontaneously hypertensive rats. (Pubmed Central) -  Sep 12, 2024   
    receptor kinase type 1, reversed the effect of TGF-?. These findings suggest that hypertension-induced retinal neurodegeneration involves inflammation, apoptosis, necroptosis, and disrupted retinoid metabolism, providing potential therapeutic targets for hypertensive retinopathy.
  • ||||||||||  NCE 401 / Tium Bio, Chiesi
    Journal, Combination therapy, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. (Pubmed Central) -  Aug 6, 2024   
    As another strategy, combination of anti-CTLA4 therapy and TU2218 resulted in high complete regression (CR) rates in CT26 and WEHI-164 tumor models. In particular, immunological memory generated by the combination of anti-CTLA4 and TU2218 in the CT26 model prevented the development of tumors after additional tumor cell transplantation, suggesting that the TU2218-based combination has therapeutic potential in immunotherapy.
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Journal:  Targeting TGF beta receptor 1 in head and neck squamous cell carcinoma. (Pubmed Central) -  May 13, 2024   
    Our results indicate a high risk of death in tumorTGFBR1+|stromaTGFBR1- expressing patients. In vitro data suggest a potential radiosensitizing effect of TGFBR1 inhibition by vactosertib.
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Trial completion, Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor (clinicaltrials.gov) -  May 12, 2024   
    P1/2,  N=24, Completed, 
    Initiation date: Apr 2024 --> Oct 2024 Active, not recruiting --> Completed | Phase classification: P1b/2a --> P1/2 | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2024
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  KEYNOTE 900: Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer (clinicaltrials.gov) -  Apr 18, 2024   
    P1/2,  N=120, Active, not recruiting, 
    Suspended --> Recruiting Phase classification: P1b/2a --> P1/2 | N=67 --> 120 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jun 2021 --> May 2024
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Phase classification, Trial completion date, Trial primary completion date, Combination therapy:  CASE1A17: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) -  Apr 4, 2024   
    P1,  N=18, Active, not recruiting, 
    Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025 Phase classification: P1b --> P1 | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Apr 2023 --> Jun 2024
  • ||||||||||  Ninlaro (ixazomib) / Takeda, vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma (Section 23) -  Mar 5, 2024 - Abstract #AACR2024AACR_6710;    
    Furthermore, therapy of BCMA+ CAR T cells in combination with Vactosertib exhibited a synergistic anti-tumor effect, compared to either CAR T cells or Vactosertib. Taken together, our data provide the rationale for clinical evaluation of Vactosertib in MM and demonstrate proof-of-concept that combination of Vactosertib and either PI or cell therapy may overcome drug resistance and enhance durable patient responses.
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Review, Journal, Metastases:  Targeting transforming growth factor beta signaling in metastatic osteosarcoma. (Pubmed Central) -  Nov 29, 2023   
    For instance, Luspatercept, a TGF-? ligand trap, has been approved by the FDA for the treatment of anemia associated with myeloid dysplastic syndrome (MDS) with ring sideroblasts/mutated
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Trial completion date, Trial primary completion date:  Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients (clinicaltrials.gov) -  Nov 20, 2023   
    P2,  N=37, Recruiting, 
    ligand trap, has been approved by the FDA for the treatment of anemia associated with myeloid dysplastic syndrome (MDS) with ring sideroblasts/mutated Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Journal:  Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer. (Pubmed Central) -  Nov 6, 2023   
    This study demonstrating the potent anti-tumor effects of Vactosertib against CRC progression. Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases (clinicaltrials.gov) -  Oct 11, 2023   
    P2,  N=19, Recruiting, 
    Vactosertib combined with pomalidomide was well-tolerated at all doses, had a manageable adverse event profile and induced durable responses with 80% progression-free survival (PFS-6) at 6 months, Vactosertib reduced TGF Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Journal:  ?Np63 overexpression promotes oral cancer cell migration through hyperactivated Activin A signaling. (Pubmed Central) -  Sep 11, 2023   
    Using an orally bioavailable inhibitor of the Activin A pathway to attenuate oral cancer cell migration and invasion, we further demonstrate the targetability of this signaling axis. Our study highlights the oncogenic role of ?Np63 - Activin A - SMAD2/3 signaling and provides a basis for targeting this oncogenic pathway in oral cancers.
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor (clinicaltrials.gov) -  Sep 1, 2023   
    P1b/2a,  N=24, Active, not recruiting, 
    Our study highlights the oncogenic role of ?Np63 - Activin A - SMAD2/3 signaling and provides a basis for targeting this oncogenic pathway in oral cancers. Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Vactosertib, a Novel Transforming Growth Factor Beta (TGF () -  Aug 31, 2023 - Abstract #SOHO2023SOHO_618;    
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Patients were simultaneously treated with pomalidomide (POM; 4 mg po qd) on days 1
  • ||||||||||  T1-44 / IngenOx Therap, vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model (Section 14; Poster Board #11) -  Mar 14, 2023 - Abstract #AACR2023AACR_4897;    
    RNA sequencing analysis of mouse tumors revealed that the combination of T1-44 and vactosertib significantly altered the expression of genes involved in cancer progression, such as cell migration, extracellular matrix, and apoptotic processes. These data demonstrate that the combination therapy of T1-44 with vactosertib is synergistic for pancreatic cancer, suggesting that this novel combination therapy has value in the treatment strategy of patients with pancreatic cancer.
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Trial completion date, Trial primary completion date, Combination therapy:  CASE1A17: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) -  Jan 10, 2023   
    P1b,  N=18, Active, not recruiting, 
    These data demonstrate that the combination therapy of T1-44 with Vactosertib is synergistic for pancreatic cancer, suggesting that this novel combination therapy has value in the treatment strategy of patients with pancreatic cancer. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
  • ||||||||||  vactosertib (TEW-7197) / National OncoVenture, Medpacto
    Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies. (On Demand | Level 1, West Hall; Poster Board No. P15) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_935;    
    P1
    This phase Ib open-label study evaluates the safety and persistence (primary objectives), and the clinical and biological activity and trafficking (secondary objectives) of our novel NK cell therapy in combination with IL-2 (aldesleukin) and TGFβ receptor 1 inhibitor vactosertib...Pts will undergo low-dose lymphodepletion with fludarabine and cyclophosphamide followed by 2 infusions of NK cells, administered 14 days apart...The trial is currently open to enrollment, with 1 pt accrued at time of submission. Clinical trial information: NCT05400122.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy:  Vactosertib and Durvalumab in Gastric Cancer (clinicaltrials.gov) -  Nov 30, 2022   
    P2,  N=55, Recruiting, 
    Moreover, we could find some examples in clinical trials. Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023